Sanofi is extending $180 million in near-term payments to Kali Therapeutics as part of a global license for KT-501, reinforcing that the company is moving quickly into next-wave T-cell engager immunology. Kali’s trispecific is now in an early rheumatoid arthritis phase Ia study following patient dosing. The agreement underscores how CD3-targeting formats remain a major battleground in autoimmune disease development, with sponsors emphasizing designs intended to reduce cytokine release while maintaining B-cell depletion. Sanofi’s licensing gives it exclusive rights to develop and commercialize the asset globally. In the market, the KT-501 program contributes to a larger wave of large pharma investments in engineered T-cell engagers, where early clinical execution and safety profile differentiation will be decisive. The payments structure also reflects a high-conviction approach that front-loads funding in exchange for a pipeline option with upside tied to development and commercialization milestones.